Dipeptidyl peptidase

DGAP-News: SphingoTec to Present at the Solebury Trout's Summer Private Company Showcase

Thursday, August 6, 2020 - 12:29pm

Please click the following link to register: https://troutaccess.com/index.php/c/Summer2020PCS

Key Points: 
  • Please click the following link to register: https://troutaccess.com/index.php/c/Summer2020PCS
    SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies.
  • SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression.
  • IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.
  • For more information please visit our website: https://sphingotec.com/

DGAP-News: SphingoTec to Present at the LifeSci Partners' Summer Symposium

Friday, July 31, 2020 - 12:10pm

Please click the following link to register: https://lifesci.events/SummerSymposium

Key Points: 
  • Please click the following link to register: https://lifesci.events/SummerSymposium
    SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies.
  • SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression.
  • IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.
  • For more information please visit our website: https://sphingotec.com/

Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Monday, June 8, 2020 - 1:00pm

We look forward to continuing to work with the FDA as we advance the development of brensocatib to address this urgent medical need."

Key Points: 
  • We look forward to continuing to work with the FDA as we advance the development of brensocatib to address this urgent medical need."
  • The breakthrough therapy designation for brensocatib is based on positive results from the global randomized, double-blind, placebo-controlled Phase 2 WILLOW study of brensocatib in adults with NCFBE.
  • Insmed expects to initiate a Phase 3 program for brensocatib in bronchiectasis in the second half of 2020.
  • Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis.

Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

Wednesday, May 20, 2020 - 2:29pm

Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib.

Key Points: 
  • Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib.
  • The virtual session, titled Phase 2 Randomized Controlled Trial of DPP1 Inhibitor Brensocatib (INS1007) in Patients with Bronchiectasis: The WILLOW Study, is part of the ATS session Breaking News: Clinical Trial Results in Pulmonary Medicine.
  • Insmed will host a conference call on Wednesday, June 24, 2020 at 4:00 pm ET.
  • Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis.

TriNetX Real-World Evidence Platform Validates Outcomes of Randomized Clinical Trials

Tuesday, December 18, 2018 - 2:00pm

CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ --TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the creation of real-world evidence (RWE), today announced the results of a study confirming that the TriNetX platform successfully leverages real-world data (RWD) to generate RWE to replicate results from randomized clinical trials (RCTs).

Key Points: 
  • CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ --TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the creation of real-world evidence (RWE), today announced the results of a study confirming that the TriNetX platform successfully leverages real-world data (RWD) to generate RWE to replicate results from randomized clinical trials (RCTs).
  • The study compared the records of 46,909 patients who had taken SGLT2 inhibitors with 189,120 patients who had taken dipeptidyl peptidase-4 (DPP4) inhibitors.
  • "This cardiovascular study is just one of many examples of how the TriNetX platform is helping the research community generate real-world evidence faster and more easily than ever possible before."
  • TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought.